

Financial news for RTGN dated on 2015-06-16: Oculus Innovativs Scienccees Announces Sales of 1.65M Ruthigen Shares to Investors For \$2.75/Share

Financial news for RTGN dated on 2015-06-15: Morning Market Gainers

Financial news for RTGN dated on 2015-06-12: Ruthigen, Pulmatrix Shareholders Approve Merger

Financial news for RTGN dated on 2015-03-16: US Stock Futures Rise Ahead Of Industrial Production, Housing Data

Financial news for RTGN dated on 2015-03-16: Ruthigen, Pulmatrix Enter Merger Agreement; Combines Company to be Named Pulmatrix

Financial news for RTGN dated on 2015-03-16: Ruthigen, Pulmatrix Enter Merger Agreement

Financial news for RTGN dated on 2015-03-16: Oculus Innovative Sciences Announces Sale of 350K Shares of Ruthigen Stock for \$962,500 in Non-Dilutive Funding

Financial news for RTGN dated on 2015-02-19: Ruthigen Shares Move Higher; May be Attributed to Report of Superbug Outbreak at UCLA Medical Center

Financial news for RTGN dated on 2015-01-12: Oculus Innovative Sciences Enters Agreement to Sell Ruthigen Shares for \$5.5M in Event of Ruthigen Merger

Financial news for RTGN dated on 2014-12-26: Stocks Hitting 52-Week Lows

Financial news for RTGN dated on 2014-11-04: Ruthigen Announces First Patient Enrollment In The Phase 1/2 Human Clinical Trial of RUT58-60

Financial news for RTGN dated on 2014-10-13: Oculus Innovative Science Being Mentioned as Potential Ebola Play; Owns 42% of Ruthigen

Financial news for RTGN dated on 2014-10-08: Ruthigen Initiates Phase 1/2 RUT58-60 Clinical Trial

Financial news for RTGN dated on 2014-08-26: Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60

Financial news for RTGN dated on 2014-08-14: Ruthigen Reports Q1 EPS of \$(0.36)

Financial news for RTGN dated on 2014-07-17: Ruthigen Announces Treatment of First Human Subjects with RUT58-60

Financial news for RTGN dated on 2014-06-30: Ruthigen Reports Q1 EPS of \$(0.46), Down 100% YOY

Financial news for RTGN dated on 2014-06-12: Ruthigen Starts Clinical Trials For RUT58-60

Financial news for RTGN dated on 2014-05-02: Ruthigen Submits IND Application to FDA for Clinical Trial of RUT58-60

Financial news for RTGN dated on 2014-03-24: Six IPOs Hit Wall Street On March 21, 2014

Financial news for RTGN dated on 2014-03-21: Shares of Ruthigen Open for Trade Around \$8.30/Unit, Priced at \$7.25

Financial news for RTGN dated on 2014-03-21: IPO for Ruthigen Will Be Released for Quote at 11:25AM EDT, Open Expected at 11:40AM; Priced 2.65M Units at \$7.25/Unit

Financial news for RTGN dated on 2014-03-21: Nasdaq Confirms Ruthigen IPO to Open Today

Financial news for RTGN dated on 2014-03-21: Ruthigen Prices 2.65M Units at \$7.25/Unit

Financial news for RTGN dated on 2014-03-19: BiotechBreakthroughs Tweet: \$RTGN IPO will receive a poor reception. Those buying \$OCLS shares in anticipation best take profits before it finally opens for trading.

Financial news for RTGN dated on 2013-08-08: Ruthigen Files \$26.675M IPO, to List on NASDAQ